Granted Patent B2

US 12,453,781 · App. 17/289,616 · Granted Oct 28, 2025

Inventors: Reshma Abdulla Rangwala (Philadelphia, PA); Sandra Verploegen (Nieuwegein, NL); Esther C. W. Breij (Driebergen, NL); Oyewale O. Abidoye (Bellevue, WA); Leonardo Viana Nicacio (Redmond, WA)

Assignee: Genmab A/S

A61K47/6869A61K9/0019A61K39/3955A61K39/39558A61K45/06A61P35/00C07K16/22C07K16/36A61K2039/507A61K2039/54A61K2039/545C07K2317/24C07K2317/565

Abstract

Claims (59)

1. A method of treating cervical cancer in a subject, the method comprising administering to the subject an anti-VEGF antibody or antigen-binding fragment thereof and an antibody-drug conjugate that binds to tissue factor (TF),

wherein the antibody-drug conjugate comprises an anti-TF antibody or an antigen-binding fragment thereof conjugated to an auristatin or a functional analog thereof or a functional derivative thereof;

wherein the anti-TF antibody or antigen-binding fragment thereof of the antibody-drug conjugate comprises a heavy chain variable region and a light chain variable region,

wherein the heavy chain variable region comprises:

(i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1;

(ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; and

(iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:3,

wherein the light chain variable region comprises:

(i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:4;

(ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:5; and

(iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:6, and

wherein the CDRs of the anti-TF antibody or antigen-binding fragment thereof of the antibody-drug conjugate are defined by the IMGT numbering scheme.

2. The method of claim 1 , wherein the antibody-drug conjugate is administered at a dose ranging from about 0.65 mg/kg to about 2.1 mg/kg.

3. The method of claim 2 , wherein the antibody-drug conjugate is administered at a dose of about 0.65 mg/kg.

4. The method of claim 2 , wherein the antibody-drug conjugate is administered at a dose of about 0.9 mg/kg.

5. The method of claim 2 , wherein the antibody-drug conjugate is administered at a dose of about 1.2 mg/kg.

6. The method of claim 2 , wherein the antibody-drug conjugate is administered at a dose of about 1.3 mg/kg.

7. The method of claim 2 , wherein the antibody-drug conjugate is administered at a dose of about 2.0 mg/kg.

8. The method of claim 1 , wherein the antibody-drug conjugate is administered once about every 3 weeks.

9. The method of claim 1 , wherein the antibody-drug conjugate is administered once about every 1 week for 3 consecutive weeks followed by about a 1 week rest period without any administration of the antibody-drug conjugate so that each cycle time is about 28 days including the resting period.

10. The method of claim 1 , wherein the anti-VEGF antibody or antigen-binding fragment thereof is administered at a dose ranging from about 5 mg/kg to about 20 mg/kg.

11. The method of claim 1 , wherein the anti-VEGF antibody or antigen-binding fragment thereof is administered at a dose of about 7.5 mg/kg.

12. The method of claim 1 , wherein the anti-VEGF antibody or antigen-binding fragment thereof is administered at a dose of about 15 mg/kg.

13. The method of claim 1 , wherein the anti-VEGF antibody or antigen-binding fragment thereof is administered once about every 3 weeks.

14. The method of claim 1 , wherein the subject has been previously treated with one or more therapeutic agents and did not respond to the previous treatment, relapsed after the previous treatment or has experienced disease progression during the previous treatment, wherein the one or more therapeutic agents does not comprise the antibody-drug conjugate.

15. The method of claim 14 , wherein the one or more therapeutic agents is selected from the group consisting of a chemotherapeutic agent, bevacizumab, cisplatin, carboplatin, paclitaxel, topotecan, a combination of bevacizumab and paclitaxel, a combination of bevacizumab and cisplatin, a combination of bevacizumab and carboplatin, a combination of paclitaxel and topotecan, a combination of bevacizumab and topotecan, a combination of bevacizumab, cisplatin and paclitaxel, a combination of bevacizumab, carboplatin and paclitaxel, and a combination of bevacizumab, paclitaxel and topotecan.

16. The method of claim 1 , wherein the subject is not a candidate for curative therapy.

17. The method of claim 1 , wherein the cervical cancer is an adenocarcinoma, an adenosquamous carcinoma, or a squamous cell carcinoma.

18. The method of claim 1 , wherein the cervical cancer is an advanced stage cervical cancer, an advanced stage metastatic cervical cancer, or a recurrent cervical cancer.

19. The method of claim 1 , wherein the anti-TF antibody or antigen-binding fragment thereof of the antibody-drug conjugate is a monoclonal antibody or a monoclonal antigen-binding fragment thereof.

20. The method of claim 1 , wherein the anti-TF antibody or antigen-binding fragment thereof of the antibody-drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:8.

21. The method of claim 1 , wherein the anti-TF antibody of the antibody-drug conjugate is tisotumab.

22. The method of claim 1 , wherein the antibody-drug conjugate further comprises a linker between the anti-TF antibody or antigen-binding fragment thereof and the auristatin.

23. The method of claim 22 , wherein the linker is a cleavable peptide linker, wherein the cleavable peptide linker has a formula: -MC-vc-PAB-, wherein:

a) MC is:

b) vc is the dipeptide valine-citrulline, and

c) PAB is:

24. The method of claim 22 , wherein the auristatin is MMAE, wherein the linker is attached to MMAE, wherein the antibody-drug conjugate has the following structure:

wherein p denotes a number from 1 to 8, S represents a sulfhydryl residue of the anti-TF antibody, and Ab designates the anti-TF antibody or antigen-binding fragment thereof.

25. The method of claim 24 , wherein the average value of p in a population of the antibody-drug conjugates is about 4.

26. The method of claim 1 , wherein the antibody-drug conjugate is tisotumab vedotin.

27. The method of claim 1 , wherein the route of administration for the antibody-drug conjugate is intravenous.

28. The method of claim 1 , wherein the anti-VEGF antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises:

(i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:17;

(ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:18; and

(iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:19,

wherein the light chain variable region comprises:

(i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:20;

(ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:21; and

(iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:22, and

wherein the CDRs of the anti-VEGF antibody or antigen-binding fragment thereof are defined by the Kabat numbering scheme.

29. The method of claim 1 , wherein the anti-VEGF antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:31 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:32.

30. The method of claim 1 , wherein the anti-VEGF antibody is bevacizumab.

31. The method of claim 1 , wherein the anti-VEGF antibody is a biosimilar of bevacizumab.

32. The method of claim 1 , wherein one or more therapeutic effects in the subject is improved after administration of the antibody-drug conjugate and the anti-VEGF antibody or antigen-binding fragment thereof relative to a baseline.

33. The method of claim 32 , wherein the one or more therapeutic effects is selected from the group consisting of: size of a tumor derived from the cancer, objective response rate, duration of response, time to response, progression free survival and overall survival.

34. The method of claim 1 , wherein the subject has one or more adverse events or is at risk of developing one or more adverse events and is further administered an additional therapeutic agent to eliminate or reduce the severity of the one or more adverse events.

35. The method of claim 34 , wherein the one or more adverse events is conjunctivitis, conjunctival ulceration, and/or keratitis and the additional agent is a preservative-free lubricating eye drop, an ocular vasoconstrictor, antibiotic, and/or a steroid eye drop.

36. The method of claim 1 , wherein the antibody-drug conjugate comprises an anti-TF antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof.

Assignments (6)

Continuity (2)

References Cited (400)